Skip to main content
. 2014 Nov 24;171(24):5881–5897. doi: 10.1111/bph.12893

Figure 4.

Figure 4

The concomitant treatment with low doses of BD-1047 and fluorocitrate also reduced the development of MA, but had no effect on CCI-induced TH. (A) I.t. injection of BD-1047 in CCI mice blocked the increase in response frequency (%) that occurring in vehicle-treated CCI mice in a dose-dependent manner. (B) However, the decrease in response latency (s) to heat stimuli was unaffected by repeated i.t. treatment with even the highest dose of BD-1047 tested (100 nmol). (C, D) Repeated daily treatment with fluorocitrate significantly attenuated MA, but not TH as compared with the vehicle-treated group (E, F). When a combination of BD-1047 and fluorocitrate was given, MA was reduced, compared with the effects shown in either the BD-1047 or fluorocitrate alone treatment groups. TH was not affected by concomitant BD-1047 and fluorocitrate treatment. *P < 0.05, **P < 0.01 and ***P < 0.001 as compared with those of CCI + VEH group.